Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Cost of Revenue (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Cost of Revenue for 7 consecutive years, with $10570.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 42.06% year-over-year to $10570.0, compared with a TTM value of $25547.0 through Sep 2025, up 3.29%, and an annual FY2024 reading of $28072.0, changed N/A over the prior year.
  • Cost of Revenue was $10570.0 for Q3 2025 at BioRestorative Therapies, up from $8729.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $18243.0 in Q3 2024 and bottomed at $2909.0 in Q1 2025.